Skip to main content

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Publication ,  Journal Article
Kostakoglu, L; Schöder, H; Johnson, JL; Hall, NC; Schwartz, LH; Straus, DJ; LaCasce, AS; Jung, S-H; Bartlett, NL; Canellos, GP; Cheson, BD ...
Published in: Leuk Lymphoma
November 2012

Our objective was to validate the International Harmonization Project (IHP) positron emission tomography (PET) response criteria and correlate with the Deauville criteria and diagnostic computed tomography-based (dCT) lesion size changes. All patients were recruited prospectively to the Cancer and Leukemia Group B (CALGB) 50203 trial for the treatment of stage I-II, non-bulky Hodgkin lymphoma (HL). [(18)F]Fluorodeoxyglucose (FDG) PET and dCT were performed at baseline and after two doxorubicin, vinblastine and gemcitabine (AVG) cycles (PET-2, dCT-2) in 88 patients. IHP and Deauville criteria and percent decrease in the sum of the products of the perpendicular diameters (%SPPD) after two cycles were correlated with progression-free survival (PFS). After a median follow-up of 3.3 years, 23.9% of patients relapsed/progressed (3-year PFS 77%). By IHP, the 2-year PFS was 88% and 54% for PET-2 negative and positive groups, respectively (p = 0.0009). Similar results were obtained for Deauville criteria. In a univariate analysis, PET-2 predicted PFS better than %SPPD, and in a combinatorial analysis, in the PET-2 positive group, a negative dCT-2 increased PFS by 27-35%. However, some confidence intervals were large due to small sample sizes. In conclusion, IHP and Deauville criteria-based interpretation of PET-2 was strongly associated with 2-year PFS. The combined analysis of PET-2 with dCT-2 suggested a better predictive value for PFS compared to either test alone. Further studies are under way to confirm these findings.

Duke Scholars

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

November 2012

Volume

53

Issue

11

Start / End Page

2143 / 2150

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Radiopharmaceuticals
  • Prospective Studies
  • Positron-Emission Tomography
  • Neoplasm Staging
  • Multimodal Imaging
  • Middle Aged
  • Immunology
  • Humans
  • Hodgkin Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kostakoglu, L., Schöder, H., Johnson, J. L., Hall, N. C., Schwartz, L. H., Straus, D. J., … Cancer Leukemia Group B, . (2012). Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma, 53(11), 2143–2150. https://doi.org/10.3109/10428194.2012.676173
Kostakoglu, Lale, Heiko Schöder, Jeffrey L. Johnson, Nathan C. Hall, Lawrence H. Schwartz, David J. Straus, Ann S. LaCasce, et al. “Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?Leuk Lymphoma 53, no. 11 (November 2012): 2143–50. https://doi.org/10.3109/10428194.2012.676173.
Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung S-H, Bartlett NL, Canellos GP, Cheson BD, Cancer Leukemia Group B. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov;53(11):2143–2150.

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

November 2012

Volume

53

Issue

11

Start / End Page

2143 / 2150

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Radiopharmaceuticals
  • Prospective Studies
  • Positron-Emission Tomography
  • Neoplasm Staging
  • Multimodal Imaging
  • Middle Aged
  • Immunology
  • Humans
  • Hodgkin Disease